Oppenheimer Initiates Coverage on BioMarin Pharmaceutical (BMRN)
More News related to BMRN
- BioMarin to Host Third Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, October 28 at 5:00 p.m. ET (23:00 CET)
- BioMarin Opens Office in Brisbane to Support Expanding Operations
- Kuvan Receives Positive Opinion From CHMP for European Approval
- BioMarin Corrects Information Included in Bloomberg Article
- William Blair & Company Initiates Coverage of BioMarin Pharmaceutical Inc. With Outperform Rating
More News related to New Coverage
- Morgan Stanley Starts Interpublic Group (IPG) at Underweight
- Morgan Stanley Starts Omnicom Grou (OMC) at Underweight
- JP Morgan Starts Harley-Davidson (HOG) at Neutral
- Keefe, Bruyette and Woods Initiates Coverage on Lakeland Bancorp (LBAI) with a Market Perform
- Morgan Stanley Upgrades Nokia (NOK) and Alcatel-Lucent (ALU) to Overweight
Oppenheimer initiates coverage on BioMarin Pharmaceutical (Nasdaq: BMRN) with a Perform.
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
Related Categories
New CoverageStocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
